Janssen turns to Danish startup for pill to replace the need to inject drugs

Danish biotech firm Biograil, founded by two former Egalet researchers, has entered a partnership with major pharmaceutical company Janssen and is poised to raise new capital.

Biograil CEO Karsten Lindhardt and CTO Nikolaj Skak. | Photo: Biograil / PR

In the beginning of 2020, when MedWatch interviewed the people behind the young biotech firm Biograil, they indicated that they were looking for partners within the pharmaceutical industry. Now – just under a year later – they managed to poach the first one.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs